High anti-TNFα concentrations are not associated with more adverse events in pediatric inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition Nov 26, 2021
Zvuloni M, Matar M, Levi R, et al. - Since risks for adverse events are associated with anti-tumor necrosis factor alpha (anti-TNFα) therapy for refractory pediatric inflammatory bowel disease (IBD), this study was run to unveil the association between anti-TNFα trough levels and adverse events rate among pediatric patients suffering from IBD.
A total of 135 pediatric patients with IBD (59 [43.7%] girls, mean age at diagnosis 12.9 [±3] years, 111 [82.2%] Crohn disease) who were treated with anti-TNFα agents and had sequential monitoring of trough concentration (TC) (1589 measurements) were analyzed retrospectively.
A median follow-up of 1.7 years (IQR 1.1–2.7) revealed the occurrence of 156 adverse events in 50 patients (37%).
There was no association of higher TCs with higher rate of anti-TNFα-related adverse events.
Whereas, such adverse events (excluding increase in liver transaminases) were related to younger age.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries